Ryu Hyo Seon, Park In Ja, Ahn Bo Kyung, Park Min Young, Kim Min Sung, Kim Young Il, Lim Seok-Byung, Kim Jin Cheon
Division of Colon and Rectal Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ann Coloproctol. 2023 Oct;39(5):410-420. doi: 10.3393/ac.2022.00143.0020. Epub 2022 Apr 28.
This study aimed to evaluate the predictive value of lymph node yield (LNY) for survival outcomes according to tumor response after preoperative chemoradiotherapy (PCRT) in patients with rectal cancer.
This study was a retrospective study conducted in a tertiary center. A total of 1,240 patients with clinical stage II or III rectal cancer who underwent curative resection after PCRT between 2007 and 2016 were included. Patients were categorized into the good response group (tumor regression grade [TRG], 0-1) or poor response group (TRG, 2-3). Propensity score matching was performed for age, sex, and pathologic stage between LNY of ≥12 and LNY of <12 within tumor response group. The primary outcome was 5-year disease-free survival (DFS) and overall survival (OS).
LNY and positive lymph nodes were inversely correlated with TRG. In good responders, 5-year DFS and 5-year OS of patients with LNY of <12 were better than those with LNY of ≥12, but there was no statistical significance. In poor responders, the LNY of <12 group had worse survival outcomes than the LNY of ≥12 group, but there was also no statistical significance. LNY of ≥12 was not associated with DFS and OS in multivariate analysis.
LNY of <12 showed contrasting outcomes between the good and poor responders in 5-year DFS and OS. LNY of 12 may not imply adequate oncologic surgery or proper staging in rectal cancer patients treated by PCRT. Furthermore, a decrease in LNY should be comprehended differently according to tumor response.
本研究旨在评估直肠癌患者术前放化疗(PCRT)后,根据肿瘤反应情况,淋巴结获取量(LNY)对生存结局的预测价值。
本研究是在一家三级中心进行的回顾性研究。纳入了2007年至2016年间接受PCRT后行根治性切除术的1240例临床II期或III期直肠癌患者。患者被分为反应良好组(肿瘤退缩分级[TRG],0 - 1)或反应不佳组(TRG,2 - 3)。在肿瘤反应组内,对LNY≥12和LNY<12的患者按年龄、性别和病理分期进行倾向评分匹配。主要结局为5年无病生存率(DFS)和总生存率(OS)。
LNY和阳性淋巴结与TRG呈负相关。在反应良好的患者中,LNY<12的患者5年DFS和5年OS优于LNY≥12的患者,但无统计学意义。在反应不佳的患者中,LNY<12组的生存结局比LNY≥12组差,但也无统计学意义。多因素分析中,LNY≥12与DFS和OS无关。
LNY<12在5年DFS和OS方面,反应良好和反应不佳的患者呈现出相反的结果。对于接受PCRT治疗的直肠癌患者,LNY为12可能并不意味着充分的肿瘤手术或准确的分期。此外,应根据肿瘤反应对LNY的降低进行不同的理解。